Clinical Trial Update: Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose rituximab for thrombotic thrombocytopenic purpura has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Thrombotic Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED | Results posted: 2021-08-13